ERBB2 and breast carcinoma: Moreover, when trastuzumab was combined with metformin to treat PIK3CA-mutated HER2+ breast carcinomas, tumor volume decreased sharply, thus suggesting that metformin is sufficient to overcome in vivo primary resistance to trastuzumab in these tumors [71].